BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 29681510)

  • 21. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
    Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
    Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrome genetic backgrounds.
    Gant VU; Junco JJ; Terrell M; Rashid R; Rabin KR
    PLoS One; 2021; 16(1):e0244863. PubMed ID: 33411777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
    Clappier E; Grardel N; Bakkus M; Rapion J; De Moerloose B; Kastner P; Caye A; Vivent J; Costa V; Ferster A; Lutz P; Mazingue F; Millot F; Plantaz D; Plat G; Plouvier E; Poirée M; Sirvent N; Uyttebroeck A; Yakouben K; Girard S; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
    Leukemia; 2015 Nov; 29(11):2154-61. PubMed ID: 26050650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
    Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
    JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.
    Ge Z; Gu Y; Zhao G; Li J; Chen B; Han Q; Guo X; Liu J; Li H; Yu MD; Olson J; Steffens S; Payne KJ; Song C; Dovat S
    Oncotarget; 2016 Aug; 7(31):49722-49732. PubMed ID: 27391346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
    Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent somatic mutations and low germline predisposition mutations in Korean ALL patients.
    Shin SY; Lee H; Lee ST; Choi JR; Jung CW; Koo HH; Kim SH
    Sci Rep; 2021 Apr; 11(1):8893. PubMed ID: 33903686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
    Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
    Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India.
    Gupta SK; Bakhshi S; Gupta R; Sharma P; Pushpam D; Sahoo RK; Kamal VK
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e666-e673. PubMed ID: 33906825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency.
    Boutboul D; Kuehn HS; Van de Wyngaert Z; Niemela JE; Callebaut I; Stoddard J; Lenoir C; Barlogis V; Farnarier C; Vely F; Yoshida N; Kojima S; Kanegane H; Hoshino A; Hauck F; Lhermitte L; Asnafi V; Roehrs P; Chen S; Verbsky JW; Calvo KR; Husami A; Zhang K; Roberts J; Amrol D; Sleaseman J; Hsu AP; Holland SM; Marsh R; Fischer A; Fleisher TA; Picard C; Latour S; Rosenzweig SD
    J Clin Invest; 2018 Jul; 128(7):3071-3087. PubMed ID: 29889099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large deletions of the 5' region of IKZF1 lead to haploinsufficiency in B-cell precursor acute lymphoblastic leukaemia.
    Morel G; Deau MC; Simand C; Caye-Eude A; Arfeuille C; Ittel A; Miguet L; Mauvieux L; Herbrecht R; Paillard C; Strullu M; Cavé H; Chan S; Kastner P; Heizmann B
    Br J Haematol; 2019 Sep; 186(5):e155-e159. PubMed ID: 31148164
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
    Song C; Gowda C; Pan X; Ding Y; Tong Y; Tan BH; Wang H; Muthusami S; Ge Z; Sachdev M; Amin SG; Desai D; Gowda K; Gowda R; Robertson GP; Schjerven H; Muschen M; Payne KJ; Dovat S
    Blood; 2015 Oct; 126(15):1813-22. PubMed ID: 26219304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
    Wang H; Song C; Ding Y; Pan X; Ge Z; Tan BH; Gowda C; Sachdev M; Muthusami S; Ouyang H; Lai L; Francis OL; Morris CL; Abdel-Azim H; Dorsam G; Xiang M; Payne KJ; Dovat S
    J Biol Chem; 2016 Feb; 291(8):4004-18. PubMed ID: 26655717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?
    Palmi C; Valsecchi MG; Longinotti G; Silvestri D; Carrino V; Conter V; Basso G; Biondi A; Kronnie GT; Cazzaniga G
    Haematologica; 2013 Aug; 98(8):1226-31. PubMed ID: 23585525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
    Boer JM; van der Veer A; Rizopoulos D; Fiocco M; Sonneveld E; de Groot-Kruseman HA; Kuiper RP; Hoogerbrugge P; Horstmann M; Zaliova M; Palmi C; Trka J; Fronkova E; Emerenciano M; do Socorro Pombo-de-Oliveira M; Mlynarski W; Szczepanski T; Nebral K; Attarbaschi A; Venn N; Sutton R; Schwab CJ; Enshaei A; Vora A; Stanulla M; Schrappe M; Cazzaniga G; Conter V; Zimmermann M; Moorman AV; Pieters R; den Boer ML
    Leukemia; 2016 Jan; 30(1):32-8. PubMed ID: 26202931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined analysis of
    Cui L; Gao C; Wang CJ; Zhao XX; Li WJ; Li ZG; Zheng HY; Wang TY; Zhang RD
    Leuk Lymphoma; 2021 Feb; 62(2):410-418. PubMed ID: 33054468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia.
    Qazi S; Uckun FM
    Haematologica; 2013 Dec; 98(12):e151-2. PubMed ID: 24323986
    [No Abstract]   [Full Text] [Related]  

  • 38. The prognostic value of IKZF1
    Kicinski M; Arfeuille C; Grardel N; Bakkus M; Caye-Eude A; Plat G; Ferster A; Uyttebroeck A; De Moerloose B; Rohrlich P; Suciu S; Bertrand Y; Cavé H
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30313. PubMed ID: 36971444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of IKZF1 deletions and IKZF1
    Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
    Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia.
    Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.